Advanced Concepts to Support Drug Development of Potent Compounds from R&D through Manufacturing (Boot Camp II)

Published: 11-Jan-2013

7 March 2013

One-day course

San Francisco, CA, US


A one-day advanced course with a focus on case studies and problem-solving to address potent compound safety issues in discovery, development, contract manufacturing and commercialisation using the 'systematic' approach and the implementation of a comprehensive programme required to support drug R&D and manufacturing organisations.

A suggested pre-requisite for the Advanced Concepts course is previous attendance at SafeBridge Potent Compound Safety Boot Camp I and/or significant experience in environmental health and safety applications in the pharmaceutical industry.

Delegates are free to register for one or both courses.

Organiser: SafeBridge Consultants

Trending Articles

  1. ASGCT Annual Meeting 2024 7-11 May, 2024 | Meeting | Portland, OR
  2. CPhI North America 7-9 May 2024 | Exhibition | Pennsylvania, US
  3. Cleanroom Conference UK 22–23 May 2024 | Exhibition | Birmingham, UK
  4. CPhI Worldwide 2011 <b>25 - 27 October 2011</b><br> Messe Frankfurt
  5. Lounges 23-25 April 2024 | Conference | Messe Karlsruhe, Germany

You may also like

Regulatory

Understanding Potent Compound Safety — A Primer for Non-EHS Professionals

13 July | Workshop | Oakbrook Terrace, Illinois
Regulatory

Industrial Hygiene in the Pharmaceutical Industry

11 – 12 July | Workshop | Oakbrook Terrace, Illinois
Containment

Potent Compound Safety: Boot Camp I

04 - 05 April 2017, Training, San Diego, CA, USA
Containment

Potent Compound Safety: Boot Camp I

16 - 17 May 2017 Training, Lisbon, Portugal
Containment

Advanced Concepts in Potent Compound Safety: Boot Camp II

06 April 2017, Training, San Diego, CA, USA
Containment

Advanced Concepts in Potent Compound Safety: Boot Camp II

18 May 2017, Training, Lisbon, Portugal
You need to be a subscriber to read this article.
Click here to find out more.
Training & Education

Evaluation and safe handling of ADCs and their toxic payloads: Part 2

In this second article of a two-part series, John Farris, CIH, and Robert Sussman, PhD DABT, SafeBridge Consultants, cover the safe handling of antibody-drug conjugates in pharmaceutical facilities and the control measures needed to protect workers from exposure risks
Subscribe now